Insmed Announces First Quarter 2009 Financi...(Total liabilities and stockholders' ...)

Date:5/13/2009

Total liabilities and stockholders' equity (deficit) $129,820 $4,758 INSMED INCORPORATED Consolidated Statements of Operations (in thousands, except per share data - unaudited) Three Months Ended March 31, 2009 2008 Royalties $28 $25 Grant revenue 272 - Other expanded access program income, net 2,070 2,328 Total revenues 2,370 2,353 Operating expenses: Research and development 5,868 5,368 Selling, general and administrative 3,449 1,391 Realized loss on investments - 392 Total expenses 9,317 7,151 Operating loss (6,947) (4,798) Interest income 23 279 Interest expense (242) (354) Gain on sale of asset, net 127,755 - Income (loss) before taxes 120,589 (4,873) Income tax expense 2,794 - Net income (loss) $117,795 $(4,873) Basic net income (loss) per share $0.96 $(0.04) Shares used in computing basic net profit (loss) per share 122,522 121,904 Diluted net income (loss) per share $0.96 $(0.04) Shares used in computi
'/>"/>

SOURCE Insmed Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference